{{Drugbox
| verifiedrevid = 444750715
| IUPAC_name = (3''Z'')-3-[1]benzofuro[3,2-''c''][1]benzoxepin-6(12''H'')-ylidene-''N,N''-dimethylpropan-1-amine
| image = Oxetorone.png
| width = 180
| alt = Skeletal formula of oxetorone
| image2 = Oxetorone-3D-spacefill.png
| alt2 = Space-filling model of the oxetorone molecule
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|oxetorone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 26020-55-3
| ATC_prefix = N02
| ATC_suffix = CX06
| PubChem = 6436540
|  ChemSpiderID = 21173074
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = T3XOS33TIQ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08312

<!--Chemical data-->
| chemical_formula =  
| C=21 | H=21 | N=1 | O=2 
| molecular_weight = 319.40 g/mol
| smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34
|  StdInChI = 1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3
|  StdInChIKey = VZVRZTZPHOHSCK-UHFFFAOYSA-N

}}

'''Oxetorone''' ([[International Nonproprietary Name|INN]]), as '''oxetorone fumarate''' ([[United States Adopted Name|USAN]]) (brand names '''Nocertone''', '''Oxedix'''), is a [[serotonin antagonist]], [[antihistamine]], and [[alpha blocker]] used as an [[antimigraine drug]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=https://books.google.com/books?id=A0THacd46ZsC&pg=PA1493|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1493–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA131|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="BoxtelSantoso2008">{{cite book|author1=C.J. van Boxtel|author2=B. Santoso|author3=I.R. Edwards|title=Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition|url=https://books.google.com/books?id=idbvAgAAQBAJ&pg=PA699|date=6 August 2008|publisher=IOS Press|isbn=978-1-60750-345-3|pages=699–}}</ref><ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref>

Association with [[hyperprolactinemia]] has been described.<ref name="pmid8980859">{{cite journal |author=Pradalier A |title=Hyperprolactinaemia and depression induced by oxetorone |journal=Cephalalgia |volume=16 |issue=8 |pages=560–1 |date=December 1996 |pmid=8980859 |doi= 10.1046/j.1468-2982.1996.1608560.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0333-1024&date=1996&volume=16&issue=8&spage=560}}</ref>

==References==
{{Reflist|2}}


{{Antimigraine preparations}}
{{Adrenergics}}
{{Histaminergics}}
{{Serotonergics}}
{{Tricyclics}}

[[Category:Antimigraine drugs]]
[[Category:Alpha blockers]]
[[Category:H1 receptor antagonists]]
[[Category:Serotonin antagonists]]
[[Category:Oxygen heterocycles]]
[[Category:Heterocyclic compounds (4 or more rings)]]

{{analgesic-stub}}